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for the advantage of the reader how personality and timeliness of ideas have
been major forces in the growth of our understanding of the "Wisdom of
the Body." Especially to be recommended to students interested in tracing
the background of modern concepts in neurophysiology are the essays by
Professor Horace W. Magoun on "The development of ideas relating the
mind with the brain," and Professor John F. Fulton "Historical back-
grounds of neurophysiology." In the latter Dr. Fulton draws effectively
on his associations with Sherrington and Pavlov to fix their respective roles
in the growth of our understanding of behavior. Dr. Chandler Brooks, one
of the editors of the volume, has contributed an excellent review of the
stages in "The discovery of the function of chemical mediators in trans-
mission of excitation and inhibition to effector tissues." For the student
this review should have especial interest, for here he will see the finger-
pointings to the truth a full thirty years before men's minds were prepared
to accept an explanation that challenged naught but tradition.
This selection of specific essays from the group betrays the reviewer's
special interests. They are all of high quality and each one certain to re-
ward the reader.
DONALD H. BARRON
AMINE OXIDASE INHIBITORS. By D. Wayne Woolley (and others). An-
nals of the New York Academy of Sciences, vol. 80, art. 3, pp. 551-1045.
New York, 1959. $5.00.
This volume includes the papers presented at a conference on inhibitors of
monoamine oxidase (MAO) held at the New York Academy of Sciences
on November 20-22, 1958. It presents reports ranging from structure-
activity relationships of new series of MAO inhibitors to the clinical evalu-
ation of these compounds; it should, therefore, have an appeal for a wide
variety of workers in this area of research, from laboratory investigators
to psychiatrists.
Most of the investigators at the conference agreed that the clinical prop-
erties of these compounds are interesting, promising, and worthy of further
work. It would appear from their reports that these drugs have some po-
tential value in the following clinical conditions.
1. Psychiatric disorders. This is probably the most important area of
their application. Generally, chronic schizophrenics who are apathetic or
depressed respond better than those with agitated depression or those
classified as acute schizophrenics. In this latter group, as many as 75 per
cent may be made worse by these agents. These are the findings of Bailey
et al. who also report success in refractory patients by using a combination
of an MAO inhibitor and a tranquilizer. A group from Boston (Alexander
and Berkely) illustrated the important point that careful selection of pa-
tients for therapy with iproniazid can lead to a much higher percentage
of success than poor selection. They reported a recovery rate of 88 per cent
in a group classified as psychesthenic-anhedonic in contrast to only 26 per
cent recovery among those exhibiting classical depressive reactions. A
number of other papers on the efficacy of these drugs in psychiatric dis-
orders have the same positive and optimistic tone, but it seems safe to
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say that their ultimate place in psychiatry must await many more definitive
studies. Voelkel of Berlin (Waldhaus Mental Hospital) made an interest-
ing point when he generalized that the action of the hydrazides occurs in
two phases: activity is affected first, followed by alteration of mood. Pos-
sibly the greatest single drawback to these drugs, apart from their toxicity,
is their relatively slow onset of action. There is a good likelihood that more
effective agents in this category will be introduced in the future.
2. Angina pectoris and coronary disease. Cesarman of the National
Institute of Cardiology of Mexico, who first observed the beneficial action
of iproniazid in angina pectoris, has indicated that this application was a
clear case of serendipity; and today even hints as to the mechanism of this
action are few and obscure. Nevertheless, all investigators at this confer-
ence were in agreement that good results may be expected from iproniazid
and, presumably, from related compounds. There was also general agree-
ment on the relief of pain and the mental changes produced by these com-
pounds, such as euphoria, excitement, and loss of perception of the angina.
On the other hand, there was disagreement about whether iproniazid can
correct ECG-abnormalities and change the response to the Master exercise
test. One important point which emerged from these reports is that one
obtains no therapeutic results without attendant side-effects.
3. Diseases of the gastro-intestinal tract. In a number of conditions like
colitis, hepatitis, anorexia nervosa, etc., in which patients suffer from lack
of appetite and malnutrition, Weiss and co-workers reported improvement
in appetite and sense of well-being after long-term therapy with iproniazid.
Their data strongly suggest that the appetite-improvement is a direct result
of a significant reduction in blood glucose.
4. Rheumatoid arthritis. An interesting paper by Scherbel and Harri-
son (Cleveland Clinic) demonstrated that iproniazid may have a place in
the treatment of retarded psychomotor activity, emotional lability, and
other CNS manifestations occurring in patients with rheumatoid arthritis
and related diseases. It was made clear that the drug had no effect on the
objective signs, nor did it alter the clinical laboratory data. But there was
improvement in motility and in the subjective symptoms of these patients.
It becomes apparent from the clinical papers presented here and from
those directly reporting toxicity that these drugs have a toxic potential of
considerable proportions. The toxicity of iproniazid ranges from annoying
side-effects like dizziness, urinary retention, and impotence to serious and
sometimes fatal hepatocellular changes. In general, it is felt that serious
toxicity can be avoided by keeping the dosage of iproniazid under 150 mg.
daily.
While there is no question that these drugs influence the metabolism of
amines within the organism, papers dealing with mechanism of action failed
to present rigorous evidence to support the view that inhibition of MAO
can account for all of the effects observed with these drugs. In the mind
of the reviewer there is little reason to doubt that other mechanisms are
also involved.
NICHOLAS J. GIARMAN
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